Abstract
Activated factor X (FXa) is strongly linked to various inflammatory events. This study aimed to investigate the effect of FXa on janus kinase2/signal transducers and activators of transcription3 (JAK2/STAT3) and mitogen-activated protein kinase (MAPK) phosphorylation in relation to rheumatoid arthritis (RA). It also extends its scope to explore the possible anti-arthritic effects of apixaban, a selective FXa inhibitor. Rats were allocated into normal control; complete Freund's adjuvant (CFA, 0.4 ml/4 days/12 days); FXa (120 µg/kg/day/3 days) and CFA + FXa groups as well as three treated groups including CFA + apixaban; FXa + apixaban and CFA + FXa + apixaban. Apixaban was administered at a dose of 10 mg/kg/12 h for15 days. By the end of the experimental period, tissue samples were collected for the assessment of phosphorylated (p)-JAK2, STAT3, MAPK, matrixmetalloprotein-1 (MMP-1) and protease-activated receptor 2. Furthermore, Serum interleukin-6 (IL-6), platelet-derived growth factor (PDGF), anti-citrullinated protein antibody (ACPA), 8-hydroxy-2′-deoxyguanosine (8-OHdG), plasma level of FXa and prothrombin time were evaluated. In support, histopathological and macroscopical examinations were performed. FXa activated JAK2, STAT3 and MAPK phosphorylation through activation of PAR 2, PDGF and IL-6 and concomitantly led to a significant elevation in ACPA, MMP-1 and 8-OHdG. Apixaban markedly amended FXa-induced changes. Conclusively, the current study revealed that FXa may have a drastic role in RA progression and pathogenesis at least through stimulation of JAK2/STAT3 and MAPK phosphorylation. Furthermore, apixaban exerted robust arthro-protective effects. These beneficial outcomes could be attributed to its ability to impede JAK2/STAT3 and MAPK activation, as well as to its antioxidant property.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmad SF, Ansari MA, Zoheir KM, Bakheet SA, Korashy HM, Nadeem A, Ashour AE, Attia SM (2015) Regulation of TNF-α and NF-κB activation through the JAK/STAT signaling pathway downstream of histamine 4 receptor in a rat model of LPS-induced joint inflammation. Immunobiology 220:889–898. https://doi.org/10.1016/j.imbio-2015-01-008
Andziak B, O'Connor TP, Qi W, DeWaal EM, Pierce A, Chaudhuri AR, Van Remmen H, Buffenstein R (2006) High oxidative damage levels in the longest-living rodent, the naked mole-rat. Aging Cell 5:463–471. https://doi.org/10.1111/j.1474-9726-2006-00237
Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, Kobayashi M, Iwane A, Sasako T, Okazaki Y, Ohsugi M, Takamoto I, Yamashita S, Asahara H, Akira S, Kasuga M, Kadowaki T (2011) Article adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13:401–412. https://doi.org/10.1016/j.cmet.2011.02.010
Bae J, Yang L, Rezaie AR (2010) Factor X/Xa elicits protective signaling responses in endothelial cells directly via PAR-2 and indirectly via endothelial protein C receptor-dependent recruitment. J Biol Chem 285:34803–34812. https://doi.org/10.1074/jbc.M110.163642
Barakat A, Szick-miranda K, Chang I, Guyot R, Blanc G, Cooke R, Delseny M, Bailey-serres J (2001) The organization of cytoplasmic ribosomal protein genes in the arabidopsis genome 1. Plant Physiol 127:398–415. https://doi.org/10.1104/pp.010265.398
Barrett YC, Wang J, Knabb R, Mohan P (2011) Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost 105:181–189. https://doi.org/10.1160/TH10-06-0393
Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA (2008) Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 172:309–320. https://doi.org/10.2353/ajpath.2008.070347
Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDominicis G, Altieri DC (1997) Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 99:2446–2451
Coenen D, Verschueren P, Bossuyt X, Euroimmun AI, Ccp E, Lite Q, Igg CP, Inova E (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 504:498–504. https://doi.org/10.1373/clinchem.2006.078063
Daha NA, Toes RE (2011) Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? Nat Publ Gr 7:202–203. https://doi.org/10.1038/nrrheum.2011.28
D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Macagni A, Manotti C, Bonini P (1989) Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time. Am J Clin Pathol 92:321–328
Doronin K, Flatt JW, Paolo NC, Khare R, Bammler TK, Beyer RP, Farin FM (2012) Coagulation factor X activates innate immunity to human species C adenovirus. Sciencexpress. https://doi.org/10.1038/nature03712
El-Gaphar OA, Abo-Youssef AM, Helal GK (2017) Bacterial lipopolysaccharide vigorously activate JAK2/STAT3 induced rheumatoid arthritis collate with complete freund’s adjuvant in experimental rats. Biomed Pharmacol J 10:2071–2076. https://doi.org/10.13005/bpj-1329
El-Gaphar OA, Abo-Youssef AM, Halal GK (2018) Levetiracetam mitigates lipopolysaccharide-induced JAK2/STAT3 and TLR4/MAPK signaling pathways activation in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 826:85–95. https://doi.org/10.1016/j.ejphar-2018-02-041
Gonca E (2015) Comparison of thiopental and ketamine + xylazine anesthesia in ischemia/reperfusion-induced arrhythmias in rats. Turk J Med Sci 1420:1413–1420. https://doi.org/10.3906/sag-1403-25
Hollborn M, Kohen L, Werschnik C, Tietz L, Wiedemann P, Bringmann A (2012) Activated blood coagulation factor X (FXa) induces angiogenic growth factor expression in human retinal pigment epithelial cells. Res Vis Ophthalmol 49:1–25
Ivashkiv LB, Hu X (2003) The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective ? Arthritis Rheum 48:2092–2096. https://doi.org/10.1002/art.11095
Kawai N, Nakamura T, Nagao S (2006) Early hemostatic therapy using recombinant factor VIIa in a collagenase-induced intracerebral hemorrhage model in rats. Brain Edema 20:212–217
Kelso EB, Ferrell WR, Lockhart JC, Elias-jones I, Hembrough T, Dunning L, Gracie JA, Mcinnes IB (2007) Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum 56:765–771. https://doi.org/10.1002/art.22423
Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, Kurata T, Hishikawa N, Abe K (2014) Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat. Stroke 45:2404–2410. https://doi.org/10.1161/STROKEAHA.114.005316
Krishnamurthy A, Joshua V, Hensvold AH, Jin T, Sun M, Vivar N, Ytterberg AJ, Engström M, Fernandes-cerqueira C, Amara K, Magnusson M, Wigerblad G, Kato J, Jiménez-andrade JM, Tyson K, Rapecki S, Lundberg K, Catrina S, Jakobsson P, Svensson C, Malmström V, Klareskog L, Wähämaa H, Catrina AI (2016) Identi fi cation of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 75:721–729. https://doi.org/10.1136/annrheumdis-2015-208093
Li R, Cai L, Ren D, Xie X, Hu C, Li J (2012) International immunopharmacology therapeutic effect of 7,3′-dimethoxy hesperetin on adjuvant arthritis in rats through inhibiting JAK2-STAT3 signal pathway. Int Immunopharmacol 14:157–163. https://doi.org/10.1016/j.intimp.2012.07.001
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262
Massberg S, Grahl L, Bruehl M, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16:887–896. https://doi.org/10.1038/nm.2184
Mcinnes IB, Schett G (2012) The Pathogenesis of rheumatoid arthritis. N Engl J Med Rev 23:2205–2219
Morser J (2012) Thrombomodulin links coagulation to inflammation and immunity. Curr Drug Targets 13:421–431. https://doi.org/10.2174/138945012799424606
Muhlestein JB (2010) Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 103:71–82. https://doi.org/10.1160/TH09-03-0177
Murray PJ, Murray PJ (2017) The JAK-STAT signaling pathway: input and output integration. J Immunol 178:2623–2629. https://doi.org/10.4049/jimmunol.178.5.2623
Nakase T, Moroi J, Ishikawa T (2018) Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients. Clin Transl Med 7:1–7. https://doi.org/10.1186/s40169-017-0179-9
Neurath MF, Finotto S (2011) Cytokine and growth factor reviews IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83–89. https://doi.org/10.1016/j.cytogfr.2011.02.003
Novotny F, Miletich P (1988) The Lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa. Blood 71:335–343
Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD (2012) Interactions between coagulation and complement—their role in inflammation. Semin Immunopathol 34:151–165. https://doi.org/10.1007/s00281-011-0280-x
Pawlak K, Borawski J, Naumnik B, Mysliwiec M (2003) Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 109:247–251. https://doi.org/10.1016/S0049-3848(03)00241-X
Poll T, Daan J, Boer D, Levi M (2011) The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 24:273–278. https://doi.org/10.1097/QCO.0b013e328344c078
Review I (2011) Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 9:168–173. https://doi.org/10.1111/j.1538-7836.2011.04319.x
Sansone P, Bromberg J (2017) Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol 30:1005–1014. https://doi.org/10.1200/JCO.2010.31.8907
Schett G, Zwerina J, Firestein G (2008) The p38 mitogen-activated protein kinase ( MAPK ) pathway in rheumatoid arthritis. Ann Rheum Dis 67:909–916. https://doi.org/10.1136/ard.2007.074278
Schuliga M (2015) The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediat Inflammatio 2015:1–9
Seevaratnam R, Patel BP, Hamadeh MJ (2009) Comparison of total protein concentration in skeletal muscle as measured by the bradford and lowry assays. J Biochem 145:791–797. https://doi.org/10.1093/jb/mvp037
Senden NH, Jeunhomme TM, Johan W, Heemskerk M, Wagenvoord R, Van VC, Hemker C, Buurman WA (2016) Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 161:4318–4324
Soo K, Hyun K, Choi M (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 31:543–547. https://doi.org/10.1007/s00296-010-1592-1
Takeda M, Ito W, Tanabe M, Ueki S, Kato H, Kihara J, Tanigai T, Chiba T, Yamaguchi K, Kayaba H, Imai Y, Okuyama K, Ohno I, Sasaki T, Chihara J (2009) Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase γ–deficient mice. J Allergy Clin Immunol 123(4):805–812
Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 12:2601–2613. https://doi.org/10.1038/onc.2012.347
Vignais M, Sadowski HB, Watling D, Rogers NC, Gilman M (1996) Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16:1759–1769
Wang H, Fang Y, Wang Y, Wang Z, Zou Q, Shi Y, Chen J, Peng D (2012) Inhibitory effect of curcumol on Jak2-STAT signal pathway molecules of fibroblast-like synoviocytes in patients with rheumatoid arthritis. Evid Based Complement Altern 2012:1–8. https://doi.org/10.1155/2012/746426
Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA, Blessing E (2011) Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011:1–9. https://doi.org/10.1155/2011/432080
Zimmermann B, Neumann E, Lefe S, Gay S, Mu U (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 16:458–468. https://doi.org/10.1016/j.molmed.2010.07.004
Acknowledgements
The authors are grateful to Histopathology Department, Faculty of Veterinary Medicine, Beni-Suef University, Egypt for the histopathological examination. We are also thankful to Dr/Leila A. Dashed, Medical Biochemistry, Molecular Biology and Tissue Engineering Unit, School of Medicine, Cairo University for performing the Western Blot analysis.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
El-Ghafar, O.A.M.A., Helal, G.K. & Abo-Youssef, A.M. Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways. Inflammopharmacol 28, 1253–1267 (2020). https://doi.org/10.1007/s10787-020-00693-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-020-00693-8